ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity College, London

About this trial

The aim of this study is to look at whether an Artificial Intelligence (AI) based computer program can automate two components of the radiotherapy treatment pathway to a sufficient quality standard to enable its routine clinical use. The two components include the delineation (outlining) of anatomical areas that are at risk of tumour spread and at risk of radiation damage, and the definition of the position, size and shape of the radiation beams.

The AI-based computer programs have been developed to perform tasks that would normally require direct human involvement by oncologists and medical physicists. Proposed advantages include improved treatment accuracy, as well as a reduction in the time (from weeks to minutes) and human resources needed to deliver radiotherapy, which this study will test.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Consecutive patients with histologically confirmed head and neck cancers of the oropharynx, larynx, hypopharynx and nasopharynx (Stage I-III) that have given consent for radical radiotherapy.

Consecutive histologically confirmed primary cervical cancer patients (Stage IB-IIIB including pelvic node positive) that have given consent for radical radiotherapy.

Consecutive histologically confirmed primary prostate cancer patients (T1-4N0M0) that have given consent for radical radiotherapy.

Mental capacity to understand and consent to participate in the study.

Disqualifiers

Patients requiring radiotherapy after curative surgery or surgery that is intended to remove as much of the tumour as possible.

Patients receiving palliative radiotherapy

Patients aged < 18years.

Trial population

Patients eligible for radiotherapy for head and neck, cervical or prostate cancer.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • A web-based artificial intelligence (AI) auto-planning tool

    Other intervention

    The CT scan taken at the time of treatment planning is uploaded to a web server called the Radiotherapy planning assistant which automates the contouring of target organs and areas of high-risk disease as well as defining the size, shape and number of radiotherapy beams to treat the cancer. The final plan is downloaded to the local treatment planning system where the doses are recalculated and clinical peer review is undertaken before the plan can be used clinically. In this study patients will not be treated with the AI tool but the manual plan created by the local teams.

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Proportion of radiotherapy treatment plans that have contours and dosimetry that meet pre-defined criteria for clinical acceptability

Time frame
Prior to first treatment

Secondary outcomes

1

comparison of time and human resource requirements between producing automated radiotherapy treatment plans using artificial intelligence and producing treatment plans using the standard manual pathway

Time frame
radiotherapy plan preparation process pre treatment
2

Comparison of radiotherapy treatment costs using the artificial intelligence automated pathway and standard manual planning pathway

Time frame
radiotherapy treatment plan preparation process and treatment interval

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University College, London

Lead sponsor

National Institutes of Health (NIH)

Collaborator

Rising Tide Foundation

Collaborator

Medical Research Council

Collaborator

Tata Memorial Hospital

Collaborator

Tata Memorial Centre

Collaborator

University of Stellenbosch

Collaborator

King Hussein Cancer Center

Collaborator

University of Malaya

Collaborator

University Ghent

Collaborator

M.D. Anderson Cancer Center

Collaborator

Mount Vernon Cancer Centre at Mount Vernon Hospital

Collaborator

University of Cape Town

Collaborator

National Cancer Institute (NCI)

Collaborator